Abstract
Four months of rifampin treatment for latent tuberculosis infection is safer, has superior treatment completion rates, and is as effective as 9 months of isoniazid. However, daily medication costs are higher for a 4-month rifampin regimen than a 9-month isoniazid regimen. To compare health care use and associated costs of 4 months of rifampin and 9 months of isoniazid. Health system cost comparison using all health care activities recorded during 2 randomized clinical trials. (ClinicalTrials.gov: NCT00931736 and NCT00170209). High-income countries (Australia, Canada, Saudi Arabia, and South Korea), middle-income countries (Brazil and Indonesia), and African countries (Benin, Ghana, and Guinea). Adults and children with clinical or epidemiologic factors associated with increased risk for developing tuberculosis that warranted treatment for latent tuberculosis infection. Health system costs per participant. A total of 6012 adults and 829 children were included. In both adults and children, greater health system use and higher costs were observed with 9 months of isoniazid than with 4 months of rifampin. In adults, the ratios of costs of 4 months of rifampin versus 9 months of isoniazid were 0.76 (95% CI, 0.70 to 0.82) in high-inc...Continue Reading
References
Jun 3, 2004·American Journal of Respiratory and Critical Care Medicine·Dick MenziesKevin Schwartzman
Nov 20, 2008·Annals of Internal Medicine·Dick MenziesKevin Schwartzman
Mar 21, 2009·American Journal of Respiratory and Critical Care Medicine·David P HollandJason E Stout
Jul 27, 2011·PloS One·David P HollandJason E Stout
Dec 19, 2012·Annual Review of Public Health·Christopher DyeMario Raviglione
Jun 7, 2014·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·E GospodarevskayaS B Squire
Jan 24, 2016·BMC Health Services Research·Anete TrajmanGabriela B Gomez
Oct 30, 2016·The Lancet Infectious Diseases·Hannah AlsdurfDick Menzies
Oct 26, 2016·PLoS Medicine·Rein M G J Houben, Peter J Dodd
Aug 2, 2017·Annals of Internal Medicine·Dominik ZennerMarieke J van der Werf
Feb 13, 2018·The International Journal of Health Planning and Management·Yisi LiuBeverley M Essue
Aug 2, 2018·The New England Journal of Medicine·Thierno DialloDick Menzies
Aug 2, 2018·The New England Journal of Medicine·Dick MenziesAndrea Benedetti
Oct 9, 2018·The Journal of Antimicrobial Chemotherapy·Tan N DoanEmma S McBryde
Dec 24, 2019·The Lancet Infectious Diseases·Jonathon R CampbellDick Menzies
Feb 14, 2020·MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports·Timothy R SterlingRobert Belknap
Citations
May 11, 2021·FEMS Microbiology Reviews·Andreu Coello PelegrinAlex van Belkum
Sep 15, 2021·PLoS Medicine·Olivia OxladeDick Menzies
Sep 15, 2021·PLoS Medicine·Mercedes Yanes-LaneDick Menzies